AZD4045 vs BCMA CAR-NK (Shenzhen Pregene Biopharma)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Myeloma

Shared mechanism: BCMA · full Multiple Myeloma pipeline

AZD4045

Developed by AstraZeneca

Phase 1/2 in Multiple Myelomaallogeneic CAR-T cell therapy (anti-BCMA)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: March 2031 · NCT07681596 (registry estimate)

No aligned efficacy figure on record for this race.

BCMA CAR-NK (Shenzhen Pregene Biopharma)

Developed by Shenzhen Pregene Biopharma Co., Ltd.

Phase 1/2 in Multiple Myelomaallogeneic CAR-NK cell therapy
Weak signal

NCT05652530 · Phase 1 · status unknown

This was an open-label, single-arm study with no randomization, no blinding, and no comparator arm, in only 19 participants, and it measured only safety. Results have not been posted yet.

No aligned efficacy figure on record for this race.

Results for Multiple Myeloma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAZD4045BCMA CAR-NK (Shenzhen Pregene Biopharma)
PFS, median—Not reported—Not reported
OS, median—Not reported—Not reported
ORR—Not reported—Not reported
VGPR or better—Not reported—Not reported
MRD negativity—Not reported—Not reported

PFS, median

AZD4045
—Not reported
BCMA CAR-NK (Shenzhen Pregene Biopharma)
—Not reported

OS, median

AZD4045
—Not reported
BCMA CAR-NK (Shenzhen Pregene Biopharma)
—Not reported

ORR

AZD4045
—Not reported
BCMA CAR-NK (Shenzhen Pregene Biopharma)
—Not reported

VGPR or better

AZD4045
—Not reported
BCMA CAR-NK (Shenzhen Pregene Biopharma)
—Not reported

MRD negativity

AZD4045
—Not reported
BCMA CAR-NK (Shenzhen Pregene Biopharma)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

AZD4045: no structured comparison results are available for Multiple Myeloma.

BCMA CAR-NK (Shenzhen Pregene Biopharma): no structured comparison results are available for Multiple Myeloma.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AZD4045's landscape · BCMA CAR-NK (Shenzhen Pregene Biopharma)'s landscape